Introduction: Schizophrenia is a chronic mental illness that negatively affects the quality of life of the patient and his family. Primary therapy in the treatment of schizophrenia is antipsychotics. Aims of the study: The aim of this study was to compare the quality of life of schizophrenic patients treated with depot neuroleptics preparations and patients without depot neuroleptics. Patientes and Methods: The sample size included 64 patients aged 18-65 years divided into two groups: patients treated with depot neuroleptic preparations and the control group, patients not treated with depot neuroleptics. For the investigation we used history and socio-demographic data, body weight, blood pressure, as well as quality of life questionnaire [a combination of Lancashire and Mansa questionnaire) and short scale for psychiatric evaluation (BPRS) Results: The average age of the examinees was 44.19 ± 7.785 years (experimental group: 43.31 ± 6.879 and control 45.06 ± 8.617 years). Regarding the frequent changes in mood, there were no statistically significant differences between the groups, Hi = 0000, p <0.05. A statistically significant difference between the groups was found in the presence of hallucinations (c2 = 8.400, df = 3, p = 0.038), Conclusion: It was found that the quality of life of patients treated for schizophrenia does not significantly differ, regardless of whether depot preparations are used or not; this finding is in accordance with the reports made by other authors.
(1) CENTAR ZA MENTALNO ZDRAVLJE JZU ,,DOM ZDRAVLJA" GRADIŠKA, (2) KLINIKA ZA PSIHIJATRIJU, KLINIČKI CENTAR BANJA LUKA Sažetak:Uvod: U liječenju shizofrenije neuroleptici igraju značajnu ulogu. Njihova upotreba u dužem vremenskom periodu može dovesti do gojaznosti. Cilj istraživanja: Cilj istraživanja je bio da se uporedi indeks tjelesne mase (BMI) kod dve grupe shizofrenih pacijenata; grupa liječena depo preparatima neuroleptika i grupa na peroralnim neurolepticima. Ispitanici i metode: Ispitivanjem je obuhvaćeno 64 pacijenta starosti od 18 do 65 god. koji su podijeljeni u dvije grupe: grupu pacijenata liječenih depo preparatima neuroleptika (flufenazin, haloperidol, risperidon), i kontrolnu grupu, pacijenti koji su uzimali per os terapiju (flufenazin, haloperidol, risperidon). Analizirani su: anamnestički podaci, sociodemografski podaci, arterijski krvni pritisak, tjelesna težina, tjelesna visina, i BMI. Rezultati: Prosječna starost svih ispitanika je bila 44,19±7,785 godina (eksperimentalna grupa: 43,31±6,879 i kontrolna 45,06±8,617 godina). T-testom nezavisnih uzoraka upoređeni su rezultati tjelesne težine (kg), tjelesne visine (cm) ispitanika eksperimentalne i kontrolne grupe i uočeno je da nema statistički značajne razlike. Nije bilo statistički značajne razlike u BMI između ispitivanih grupa, Hi=0000, p>0,05. Zaključak: Na osnovu sprovedenog istraživanja, može se zaključiti da nema statistički značajne razlike u BMI kod pacijenata koji boluju od shizofrenije, bez obzira da li se liječe depo preparatima neuroleptka ili neuroleptike uzimaju per os.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.